methyl 3-(6-methoxynaphthalen-2-yl)butanoate | 95093-51-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 3-(6-methoxynaphthalen-2-yl)butanoate
• 英文别名: Methyl (R)-3-(6-Methoxy-2-naphthyl)butanoate
• CAS: 95093-51-9；887401-60-7；887401-61-8
• 化学式: C₁₆H₁₈O₃
• 分子量: 258.317
• InChiKey: HXKZURLBHDVLQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-(6-methoxynaphthalen-2-yl)butanoate 在 lithium hydroxide 作用下， 以 异丙醇 为溶剂， 反应 1.0h， 以0.45 g的产率得到3-(6'-甲氧基-2'-萘基)-丁酸
  参考文献：
  名称：

  Conversion of cyclooxygenase inhibitors into hydroxythiazole 5-lipoxygenase inhibitors

  摘要：

  Representative examples of NSAID cyclooxygenase inhibitors such as naproxen, ibufenac, ibuprofen, and butibufen have been transformed into 5-lipoxygenase inhibitors by replacement of the carboxylic acid moiety with a 4-hydroxythiazole group. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(96)00255-6
• 作为产物：
  描述：

  6-甲氧基-2-乙酰萘 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 23.0 ℃ 、303.98 kPa 条件下， 反应 20.0h， 生成 methyl 3-(6-methoxynaphthalen-2-yl)butanoate
  参考文献：
  名称：

  Conversion of cyclooxygenase inhibitors into hydroxythiazole 5-lipoxygenase inhibitors

  摘要：

  Representative examples of NSAID cyclooxygenase inhibitors such as naproxen, ibufenac, ibuprofen, and butibufen have been transformed into 5-lipoxygenase inhibitors by replacement of the carboxylic acid moiety with a 4-hydroxythiazole group. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(96)00255-6

文献信息

• Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
  申请人：Colletti L. Steven

  公开号：US20070299101A1

  公开（公告）日：2007-12-27

  The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.

  本发明涉及公式（I）的烟酸受体激动剂，以及药学上可接受的盐和溶剂。这些化合物对于治疗脂质代谢异常，特别是降低血清低密度脂蛋白（LDL）、超低密度脂蛋白（VLDL）和三酰甘油，并提高高密度脂蛋白（HDL）水平是有用的。还包括药物组合物和治疗方法。
• Asymmetric palladium-catalyzed benzylic nucleophilic substitution: high enantioselectivity with the DUPHOS family ligands
  作者：Martine Assié、Jean-Yves Legros、Jean-Claude Fiaud

  DOI：10.1016/j.tetasy.2005.01.032

  日期：2005.3

  The asymmetric palladium-catalyzed benzylic reaction of 1-(2-naphthyl)ethyl acetate and its 6-methoxy substituted analogue with dimethyl malonate anion led to substitution products with up to 90% ee when the iPr-DUPHOS chiral ligand was used. (C) 2005 Elsevier Ltd. All rights reserved.
• Conversion of cyclooxygenase inhibitors into hydroxythiazole 5-lipoxygenase inhibitors
  作者：Francis A.J. Kerdesky、Clint D.W. Brooks、Keren I. Hulkower、Jennifer B. Bouska、Randy L. Bell

  DOI：10.1016/s0968-0896(96)00255-6

  日期：1997.2

  Representative examples of NSAID cyclooxygenase inhibitors such as naproxen, ibufenac, ibuprofen, and butibufen have been transformed into 5-lipoxygenase inhibitors by replacement of the carboxylic acid moiety with a 4-hydroxythiazole group. (C) 1997, Elsevier Science Ltd.